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ABSTRACT
Surgical resection of tumors is often followed by regrowth at the primary site and 
metastases may emerge rapidly following removal of the primary tumor. Macrophages 
are important drivers of tumor growth, and here we investigated their involvement 
in postoperative relapse as well as explore macrophage depletion as an adjuvant to 
surgical resection. RETAAD mice develop spontaneous metastatic melanoma that 
begins in the eye. Removal of the eyes as early as 1 week of age did not prevent 
the development of metastases; rather, surgery led to increased proliferation of 
tumor cells locally and in distant metastases. Surgery-induced increase in tumor 
cell proliferation correlated with increased macrophage density within the tumor. 
Moreover, macrophages stimulate tumor sphere formation from tumor cells of post-
surgical but not control mice. Macrophage depletion with a diet containing the CSF-1R 
specific kinase inhibitor Ki20227 following surgery significantly reduced postoperative 
tumor recurrence and abrogated enhanced metastatic outgrowth. Our results confirm 
that tumor cells disseminate early, and show that macrophages contribute both to 
post-surgical tumor relapse and growth of metastases, likely through stimulating a 
population of tumor-initiating cells. Thus macrophage depletion warrants exploration 
as an adjuvant to surgical resection.
INTRODUCTION
Surgical resection has been a standard treatment 
for solid malignancies for over a century. However, 
much controversy still surrounds this form of therapy as 
both beneficial and adverse effects have been reported. 
Although surgical resection may halt the progression of 
the cancer in the short term, recurrences can occur from 
residual tumor cells, even over a decade after the initial 
surgery [1]. Several factors have been associated with 
tumor recurrence after surgery, including growth factors 
in the wound fluid, such as TGFβ, FGF [2], HB-EGF and 
PDGF [3], as well as surgery-induced hypoxia [4] and 
oxidative stress [5]. Surgery may also promote metastasis 
by shedding tumor cells during surgery, and accelerate 
the outgrowth of already-disseminated metastases, since 
primary tumors can produce inhibitory molecules that 
regulate the growth of distant metastases [6–8].
The immune system plays an important role in the 
regulation of tumor development and progression. Post-
surgical immune suppression is associated with recurrence 
and metastatic outgrowth; natural killer cells in particular 
are suppressed, in terms of numbers and activity, by 
surgical trauma, contributing to a pro-tumoral environment 
[9, 10]. Conversely neutrophils present in post-operative 
lavage fluid can enhance growth of transplanted tumor 
cells [11], but the roles of other immune cell populations 
have yet to be characterized. Macrophage infiltration of 
tumors is associated with poor prognosis and increased 
relapse in a number of cancers [12–14]. Macrophages 
Oncotarget22858www.impactjournals.com/oncotarget
have also been well-documented to promote tumor cell 
proliferation [15], and while recent reports highlighted 
a role for macrophages in tumor responses to various 
types of therapy including chemotherapy, immunotherapy 
and radiotherapy [16–18], little is known about whether 
macrophages contribute directly to recurrence and 
metastases after surgical resection.
In the current study we used a well-characterized 
murine model of spontaneous melanoma to understand 
how macrophages contribute to post-surgical relapse 
and metastatic outgrowth. RETAAD mice are immune-
competent and develop uveal melanoma owing to 
expression of the human RET oncogene in melanocytes. 
Following development of the primary tumor in the eye 
from around three weeks of age, a rapid and progressive 
metastatic cascade occurs [19], recapitulating many 
aspects of human melanoma. Here we found that removal 
of the eyes prior to macroscopic tumor development did 
not alter the course of disease progression, but instead 
accelerated outgrowth of residual tumor cells, as well 
as of distant metastases. Surgery induced the emergence 
of a population of tumor cells that were able to respond 
to macrophage signals to initiate tumor sphere growth 
in vitro, and this capacity may be responsible for the 
enhanced tumor growth seen after surgery. Postoperative 
depletion of macrophages significantly reduced tumor 
regrowth at the primary site and abrogated the surgery-
enhanced growth of metastases.
RESULTS
Surgical resection enhances primary tumor 
regrowth
Many of the studies on surgical resection in cancer 
have been performed in mice bearing transplanted tumors, 
which poorly mimic the complexity and natural progression 
of the disease in humans. Furthermore, transplanted models 
rarely allow the simultaneous study of a recurring primary 
tumor and distant metastases in the same animal. In the 
RETAAD mice used here, the primary tumor can develop 
in the eye as early as three weeks of age, before metastases 
become evident in various distant tissues including facial 
muscles (median onset 66 days), neck/trunk (80 days), 
reproductive tract (242 days), mediastinum (263 days) and 
lungs (347 days). The traditional view that “seeding” of 
distant tissues with metastases occurs late during cancer 
progression would predict that tumor development and 
metastasis should be completely abrogated if resection of 
the eyes (primary tumor development site) was carried out 
during the early phase of tumor development. We tested 
this hypothesis: three week old RETAAD pups underwent 
bilateral visual enucleation (VE) and four weeks later were 
euthanized and necropsied. Immunohistochemistry on 
sections of the removed eyes revealed hyperplasia in the 
choroid layer, even at this young age, seen as increased 
abundance of cells expressing the melanoma marker 
S100B compared to ret –/– non-tumor bearing litter mates 
(Figure 1A), but no tumor nodules were visible. Four weeks 
after VE, new tumors were present within the eye sockets 
which were macroscopically comparable to those in non-
VE age-matched controls (Figure 1A). Similar results were 
obtained when we performed surgery in younger animals at 
one week of age. Thus, early resection of the primary tumor 
site did not prevent tumor relapse. To evaluate the kinetics of 
postsurgical tumor regrowth we conducted VE on one group 
of one week old mice and another group of three weeks old 
mice, and allowed both to reach seven weeks of age before 
necropsy and comparison to age-matched non-VE controls. 
This strategy allowed us to evaluate tumor regrowth at 
the primary site at both four and six weeks post-operation 
and minimized the number of control animals required. 
Following VE a similar number of tumor nodules grew 
in the eye sockets as in non-VE control mice (Figure 1B). 
However, tumors from VE mice contained a significantly 
higher percentage of Ki67-positive proliferating tumor 
cells compared to controls at four weeks post-operation 
(4wkPO), but not at 6wkPO (Figure 1C). The average tumor 
nodule area in VE mice at 6wkPO was significantly greater 
than in control mice, while tumor area was comparable in 
both groups at 4wkPO (Figure 1D). This indicates that eye 
surgical resection increases proliferation of tumor cells locally 
at 4wkPO, resulting in increased tumor area by 6wkPO.
Primary tumor resection enhances growth of 
pre-existing metastases
The RETAAD mice exhibit a well-defined and 
reproducible kinetic of cancer development with metastases 
evident throughout the body soon after initiation in the eyes. 
Thus we asked whether early removal of the eyes had any 
effect on the development of metastases. Conducting VE 
at either one or three weeks of age did not alter the number 
of metastases detected at necropsy compared to control 
non-VE mice (Figure 2A), indicating that metastasis was 
initiated very early, even before detectable outgrowth 
of the primary tumor. Interestingly, a similar pattern of 
increased tumor cell proliferation and tumor surface area 
in metastases of VE mice was seen at 4wkPO (Figure 2B) 
and 6wkPO (Figure 2C) respectively, as for the tumors at 
the primary sites in these mice (Figure 1C and 1D). This 
indicates that surgery results in systemic changes that not 
only affect the primary tumor/surgical site but also alter 
metastatic outgrowth.
Surgery increases macrophage infiltration which 
correlates with tumor growth
Macrophages normally infiltrate the surgical site 
to assist wound healing [20]. However, M2/tumor-
associated macrophages (TAMs) are also well known 
to promote tumor growth [21]. We therefore asked 
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whether macrophages contribute to the enhanced local 
and/or distant tumor growth observed after surgery. We 
immunolabeled sections of the relapsed primary tumors 
and of metastases using F4/80 as a marker for TAMs, 
and found that there was a significantly higher density 
of TAMs in the tumor bed at 4wkPO, but not at 6wkPO, 
compared to control non-VE mice (Figure 3A and 3B). 
These TAMs expressed the M2 marker CD206 on the cell 
surface, and Arginase 1 and TGFβ at the mRNA level 
(Supplementary Figure S1A to S1C respectively). The 
increased number of TAMs at 4wkPO did not correlate 
with the tumor area at the same time point (Figure 3C 
left panel), but did at 6wkPO (Figure 3C right panel). 
Moreover, a close association was seen between TAM 
density and percentage of Ki67+ proliferating cells within 
the tumors at 4wkPO (Figure 3D). This indicates that M2-
type TAMs within the tumors of VE mice are associated 
with increased tumor cell proliferation at 4wkPO, which 
results in increased tumor size at 6wkPO.
Surgery accelerates the emergence of 
macrophage-responsive tumor-initiating cells
Previously we have shown that RETAAD tumors 
harbor a population of tumor-initiating cells (TICs) 
which can be detected by a sphere formation assay 
similar to the neurosphere assay. These TICs possess 
the unique capacity to form abundant tumor spheres 
in vitro in response to TAM stimulation [22]. This TAM-
responsive TIC population normally emerges only in 
mice > 30 weeks of age, and is therefore a somewhat 
late event during the natural course of disease; however, 
treatment with the chemotherapeutic agent temozolamide 
drives early emergency of TAM-responsive TIC which 
Figure 1: Surgical resection enhances primary tumor regrowth. (A) IHC labeling of eye sections from non-tumor-bearing 
(ret –/–) and tumor-bearing (Ret +/–) mice, with S100B (red) and Ki67 (blue). At the time of surgery (3wk after birth) Ret +/– eyes show signs 
of hyperplasia (arrow). 4 weeks after surgery (VE), tumor regrowth has occurred and tumors were comparable to those in orbits of control 
mice. (B) Quantification of the number of tumor nodules relapsing within the orbit of the eye 4 and 6wk after surgery. Each point represent 
one mouse; 1-way ANOVA, N.S. not significant (n = 12–14 mice). (C) The percentage of Ki67+ cells in the relapsed tumors 4 and 6wks after 
surgery. Each point represents one tumor nodule; 1-way ANOVA, *P < 0.05 (n = 4–6 mice). (D) Quantification of the area of the relapsed 
tumor nodules 4 and 6wk after surgery. Each point represents one tumor nodule; 1-way ANOVA, **P < 0.01 (n = 3–5 mice).
Oncotarget22860www.impactjournals.com/oncotarget
may exacerbate tumor development. We hypothesized 
that surgical trauma also induced the emergence of the 
TAM-responsive TIC population which then contributed 
to tumor regrowth at the resected site and increased 
growth of metastases. To test this hypothesis we 
conducted VE on RETAAD mice at 10–15 weeks of age 
and characterized the behavior of their tumor cells four 
to six weeks later. This protocol is similar to the well-
validated positive-margin resection model previously 
published [23]. The use of older mice also enabled us 
to recover sufficient cells from their relatively larger 
tumors to be able to assess their capacity to form tumor 
spheres in vitro as a measure of their TIC content. For 
the tumor sphere assays, eye tumors from recovered 
VE and non-VE animals were dissociated into single 
cells, and the CD34– tumor cell population, containing 
the TAM-responsive TIC fraction [22], was enriched by 
flow cytometric removal of PDGFRα+ fibroblasts, CD31+ 
endothelial cells and CD45+ immune cells. CD11b+F4/80+ 
TAMs were isolated from within the CD45+ population 
from the tumors of old (>30 weeks) non-VE control 
mice. The CD34– tumor cells were then cultured in 
suspension cultures to form tumor spheres with or 
without TAMs, at a ratio of 1:50 (TAM: tumor cell), 
reflecting the normal abundance of TAMs within the 
tumors [24] (Supplementary Figure S2A). As expected, 
cells derived from eye tumors of old non-VE mice (> 30 
weeks) formed significantly more spheres after 5–7 days 
culture with TAMs than without TAMs, while tumor cells 
from young mice, age-matched to the VE group, did not 
(Figure 4A). Interestingly, cells derived from eye tumors 
of both the 4wkPO and 6wkPO VE group responded 
to the addition of TAMs and formed significantly more 
tumor spheres than in the absence of TAMs. The same 
results were seen when cells from metastases of VE 
mice were used: since the effect is similar, we pooled the 
data from the eye tumors and metastases into the same 
analysis to allow more robust statistical interrogation 
(Figure 4A). Thus surgical trauma promotes the emer-
gence of a population of TAM-responsive TICs in both 
the recurrent tumor as well as the metastases.
We were also curious to know whether surgical 
trauma also affected the function of the TAMs in addition 
to increasing their number. Previously we showed that the 
stimulatory activity of TAMs depends on the production 
of TGFβ and polyamines via activation of Arginase 1 
[22]. Thus we quantified the level of TGFβ and Arginase 
1 transcripts in TAMs at 6wkPO, and found that surgical 
resection of the eye significantly increased the expression 
of both genes (Supplementary Figure S2B and S2C). 
TAMs from VE mice were significantly more stimulatory 
than TAMs from non-VE mice on tumor cells from old 
control mice (Supplementary Figure S2D), while when 
tumor cells from VE mice were used, the response 
was similar to TAMs from control and VE animals 
(Supplementary Figure S2E). This suggests that there is an 
increase in TAM activity after surgery, but only old mice 
harbor TICs that can respond, while young tumor cells are 
acquiring the ability to respond to TAMs and have yet to 
reach their full responsiveness.
The kinase inhibitor Ki20227 targets specifically 
the colony stimulatory factor-1 receptor (CSF-1R), which 
is important for macrophage survival and function [25]. 
Using this inhibitor we previously showed that inhibition 
of macrophage function prevented the induction of 
TAM-responsive TICs by temozolamide [22]. Here we 
asked whether inhibition of macrophages after surgical 
resection would similarly prevent the development of 
Figure 2: Surgical resection enhances the growth of metastases. (A) Number of metastases present in mice 4 and 6wk after 
surgery. Each point represents one mouse; 1-way ANOVA, N.S. not significant (n = 8–10 mice). (B) The percentage of Ki67+ tumor cells 
present in the metastases 4 and 6wks after surgery. Each point represents one tumor nodule; 1-way ANOVA, *P < 0.05 (n = 3–5 mice). 
(C) Quantification of the area of the metastases 4 and 6wk after surgery. Each point represents one tumor nodule; 1-way ANOVA, 
*P < 0.05 (n = 3–7 mice).
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TAM-responsive TICs following VE. 10–15 week old 
mice that underwent VE were fed a normal or Ki20227-
supplemented diet during their recovery for four to six 
weeks before cells from the primary tumor site and from 
metastases were harvested for sphere-forming assays. 
Ki20227 treatment of mice significantly reduced the 
density of macrophages in tumors compared to untreated 
VE mice at 4wkPO (Figure 4B). When tumor cells from 
Ki20227-treated animals were stimulated with TAMs 
from untreated non-VE old mice they no longer increase 
sphere formation in respond (Figure 4C), indicating that 
macrophage depletion by inhibition of CSF-1R prevents 
the development of the TAM-responsive TICs after surgery.
Previously we also showed that TAMs stimulate 
tumor sphere formation from TICs in RETAAD 
melanomas by producing polyamines via the Arginase 1 
pathway: this observation would suggest that polyamine 
metabolism might be dysregulated in these tumors 
as has been reported for other tumor cell types [26]. 
To determine whether surgery similarly contributed 
to polyamine dysregulation and consequently droved 
tumor cells to exploit growth stimuli from TAMs, 
we quantified the expression of several enzymes in 
the polyamine metabolic/catabolic pathway within 
the CD34– tumor cells. We found that transcripts for 
spermine synthase (Sms), which converts spermidine to 
spermine for final usage by the cell, were significantly 
more abundant in CD34– tumor cells from VE 
animals compared to non-VE controls (Figure 4D 
left panel). The catabolic enzyme N-acetylpolyamine 
oxidase (APAO), which breaks down polyamines, was 
also increased post-surgery (Figure 4D right panel). This 
suggests that surgery increases the turnover of polyamine 
within the tumor cells, indicating that there is increased 
Figure 3: Surgery increases macrophage infiltration which correlates with tumor growth. (A) Representative 
immunofluorescence image of tumors from control and VE animals labeled with antibodies against CD45 (green) and F4/80 (red). (B) Density 
of F4/80+ TAMs in relapsed eye tumors and metastases at 4 and 6wkPO. Each point represents one tumor nodule; 1-way ANOVA, ****P < 
0.0001 (n = 3–7). (C) Graph showing the correlation (Pearson) of TAM numbers with tumor area at 4wkPO and 6wkPO at the primary site. 
(D) Graph showing the correlation (Pearson) of TAM density and percentage of Ki67+ cells within the tumors at 4wkPO at the primary site.
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polyamine consumption and consistent with the increased 
tumor growth observed in these animals. When CD34– 
tumor cells from Ki20227 treated animals were analyzed 
there was a significant reduction in Sms expression, but 
a further increase in APAO expression (Figure 4D). This 
indicates that depletion of the TAMs reduces the supply 
of polyamines leading to reduced expression of Sms 
while the increase in APAO expression further depletes 
polyamines within the tumor cells, both mechanisms 
leading to reduced tumor proliferation.
Macrophage depletion reduces tumor growth 
after surgery
The above experiments showed that depletion of 
macrophages with Ki20227 inhibits the development 
of TAM-responsive TICs and reduces expression of the 
polyamine metabolic enzyme Sms, while increasing the 
expression of the polyamine catabolic enzyme APAO. 
We may therefore expect that macrophage depletion will 
affect tumor regrowth at the primary site, as well as the 
Figure 4: Surgery accelerates the emergence of macrophage-responsive tumor-initiating cells. (A) Graph showing the 
fold-change in percentage of cells forming tumor spheres in the presence of TAMs, relative to without TAMs. Tumor cells from young 
mice (age 10–15 weeks) that underwent VE followed by recovery for 4–6wks were stimulated with TAMs derived from non-VE old mice 
(> 30wk). Bars represent mean ± SE; 2-way ANOVA, ***P < 0.001, ****P < 0.0001 (n = 3–4 mice). (B) Density of F4/80+ TAMs in primary 
relapsed tumors from mice that underwent VE followed by 4wks of recovery on a normal (4wkPO) or Ki20227-supplemented diet (4wkPO 
+ Ki), and non-VE age-matched control mice. Each point represents one tumor nodule; 1-way ANOVA, ****P < 0.0001 (n = 3–7 mice). 
(C) Graph showing the fold-change in percentage of cells forming tumor spheres in the presence of TAMs, relative to without TAMs. 
Tumor cells from VE mice on normal (VE) or Ki20227 diet (VE+Ki) were stimulated with TAMs derived from non-VE old mice. Bars 
represent mean ± SE; 2-way ANOVA, ****P < 0.0001, N.S. not significant (n = 3–4 mice). (D) Graph showing the gene expression level of 
Sms (left panel) and APAO (right panel) in CD34– tumor cells derived from VE mice on normal (VE) or Ki20227 diet (VE+Ki) and non-VE 
age-matched control mice. Each point represents one mouse; 1-way ANOVA, *P < 0.05 (n = 6–7 mice).
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growth of metastases following surgery. Returning to the 
original experimental plan with VE performed on mice 
of one or three weeks of age, we now added Ki20227 
treatment post-surgery. We found that Ki20227 treatment 
significantly reduced the percentage of Ki67+ proliferating 
tumor cells at 4wkPO relative to primary site tumors from 
untreated VE mice (Figure 5A), and that by 6wkPO this 
translated into significantly smaller tumor size (Figure 5B). 
The same effect was also observed for the metastases; 
significantly lower percentages of proliferating cells within 
tumors at 4wkPO (Figure 5C) and reduced tumor size at 
6wkPO (Figure 5D). Interestingly, Ki20227 treatment not 
only abrogated the enhancement of tumor regrowth at the 
primary site that was associated with VE, but reduced 
the size of tumors to significantly below that of non-VE 
control animals (Figure 5B). In the case of the metastases, 
only the enhanced growth after surgery was abrogated 
by Ki20227 treatment (Figure 5D). This effect did not 
relate to differences in extent of macrophage depletion, 
as tumors at the primary site and metastases both showed 
approximately 75% reduction in macrophages density with 
Ki20227 treatment (data not shown). Thus our data show 
that macrophage depletion following surgical resection 
can significantly reduce the size of relapsed tumors at the 
primary site as well as limiting the enhanced growth of 
any metastases disseminated prior to surgery.
DISCUSSION
In the RETAAD mice, disseminated tumor cells can 
be detected in various internal organs from 3 weeks of age 
[19]. However, our current data show that the development 
of metastases was unaffected even when the eyes were 
resected at 1 week of age: this suggests that tumor cells 
may disseminate much earlier than previously thought. 
While we did not formally exclude the possibility that 
the multiple lesions observed may have derived from 
independent transformation events, our previous SNP 
analysis strongly argues against this, instead indicating 
that the multiple lesions in RETAAD mice do originate 
from the primary eye tumor [19]. Thus dissemination is 
likely to have occurred during the hyperplastic lesion 
stage, supporting earlier observations in melanoma [27] 
and cervical cancer [28] patients. This has profound 
implications for cancer therapy. Since any therapeutic 
intervention will likely alter the microenvironments of 
disseminated tumor cells, as well as treating the cancer, 
it runs the risk of driving metastatic exit from a dormant 
state and initiating outgrowth. Indeed, surgery- associated 
metastatic escape from dormancy has been documented 
for several types of cancer [29].
In our current work we show that macrophages 
play an important role in tumor recurrence and metastatic 
outgrowth following surgical resection of the primary 
tumor. Macrophages are one of the first cell types to enter 
the postsurgical site and are essential for wound healing 
[20]. They are an important source of TGFβ which regulates 
critical steps of wound healing. TGFβ is also known to 
promote tumor growth. Accordingly, inhibition of TGFβ can 
prevent postoperative tumor relapse in a murine model of 
mesothelioma [30]. Thus it is surprising how little is known 
about the contribution of macrophages to the progression of 
cancer following surgery. We show here that the increased 
density of macrophages in both the relapsing tumor and 
the metastases of postoperative mice is associated with 
increased tumor proliferation and growth in the weeks 
following surgery. Macrophage depletion with Ki20227 
reduced growth of tumors at the primary site significantly 
below even non-VE controls, indicating that resection 
combined with macrophage depletion might be an effective 
clinical approach to reduce postoperative local tumor 
recurrence. The anatomy of the orbital structure may have 
limited our ability to achieve complete removal of early 
locally-disseminated cells or increased shedding of primary 
tumor cells during surgery. Therefore individuals bearing 
tumors in sites more amenable to complete resection may 
see greater benefit if surgery is combined with macrophage 
depletion. The effect of macrophage depletion was also 
evident at the metastatic sites, supporting the use of systemic 
macrophage inhibition as opposed to a local approach at 
the wound site. A cautionary consideration in applying 
macrophage depletion relates to the role of macrophages 
in wound healing. Although we did not observe wound 
healing defects with Ki20227, preliminary experiments 
using clodronate liposome applied directly to the surgical 
site resulted in poor wound healing (data not shown). 
A possible explanation for this difference is that Ki20227 did 
not deplete the macrophages completely but rather limited 
the increase in macrophages following surgery, while 
clodronate liposome applied directly to the surgical site 
may have a more drastic effect on macrophage infiltration 
therefore preventing wound healing. Thus, further work will 
be necessary to identify optimal conditions for macrophage 
depletion before it can be used in the clinics.
Macrophages have previously been reported to 
regulate the metastatic process, promoting metastatic 
phenotypes in tumor cells [31], and regulating both 
intravasation of tumor cells into blood vessels [32] and their 
extravasation at the metastatic site [33]. However, these 
mechanisms did not seem to be of primary importance in 
the current study; where the total number of metastases was 
unaffected by either surgery or Ki20227 treatment (data not 
shown), presumably as a result of the early dissemination 
evident from the VE studies in 1 week old mice.
We propose that macrophages contribute to 
postsurgical tumor relapse and metastatic growth by 
stimulating a population of CD34– TICs. The observation 
that tumor cells from young mice do not normally respond 
to macrophage stimulation, but can acquire the ability to 
respond after surgery, is similar to our previous observation 
in chemotherapy-treated young mice [22]. This supports 
the hypothesis that melanoma-initiating cells are flexible 
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and can switch phenotypes [34] in response to a changing 
microenvironment. This observation substantially increases 
the complexity of therapeutic development. Previously we 
found that chemotherapy not only induced the tumor cells 
to change their responsiveness to macrophages, but that 
the macrophages from chemotherapy-treated mice also 
became more stimulatory, together resulting in a much 
greater induction of tumor sphere formation in vitro. In the 
current study, surgery also induced the appearance of the 
macrophage-responsive TICs and increased the stimulatory 
activity of the macrophages, reflected in increased TGFβ 
and Arginase 1 expression as well as their ability to 
stimulate control tumor cells to a greater extent than control 
macrophages (Supplementary Figure S2). However, 
tumor cells from the VE animals responded equally to 
macrophages from control and VE mice. This suggests 
that there may be multiple populations of tumor cells in 
older mice capable of responding to subtle changes in the 
macrophages, while younger tumor cells are acquiring new 
survival skills after surgery. Given the myriad of growth-
stimulatory signals in the healing wound, responsiveness 
to macrophage stimulation is likely to contribute only 
Figure 5: Macrophage depletion reduces tumor growth after surgery. (A) Percentage of Ki67+ cells in relapsed eye tumors 
from VE mice on normal (VE) or Ki20227 diet (VE+Ki) compared with non-VE age-matched control mice. Each point represents one 
tumor nodule; 1-way ANOVA, *P < 0.05 (n = 4–6 mice). (B) Area of relapsed eye tumors from VE mice on normal (VE) or Ki20227 
diet (VE+Ki) compared with non-VE age-matched control mice. Each point represents one tumor nodule; 1-way ANOVA, **P < 0.01 
(n = 3–5 mice). (C) Percentage of Ki67+ cells in metastases from VE mice on normal (VE) or Ki20227 diet (VE+Ki) compared with non-VE 
age-matched control mice. Each point represents one tumor nodule; 1-way ANOVA, *P < 0.05 (n = 3–5 mice). (D) Area of metastases from 
VE mice on normal (VE) or Ki20227 diet (VE+Ki) compared with non-surgical age-matched control mice. Each point represents one tumor 
nodule; 1-way ANOVA, *P < 0.05, **P < 0.01 (n = 3–7 mice).
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partially to tumor recurrence, as can be seen by the inability 
of macrophage depletion to completely inhibit tumor 
regrowth. Similarly the presence of other immune cells such 
as neutrophils and myeloid-derived suppressor cells as well 
as endothelial cells and tumor-associate fibroblasts may 
also contribute to postsurgical tumor growth. Nevertheless, 
limiting the effect of macrophages will likely contribute to 
positive postsurgical outcomes.
Previously we have shown that the main 
stimulatory signals from TAMs are TGFβ and poly-
amines: here we reveal that surgery can also increase 
polyamine metabolism in the tumor cells which may 
drive their dependency on macrophages as a source of 
polyamines. Ki20227 treatment reduced expression of 
the metabolic enzyme, while increasing those for the 
catabolic enzyme, indicating that macrophage depletion 
may impact tumor growth by removing the source 
of polyamine. A number of polyamine inhibitors are 
currently in clinical trials and may add to the repertoire 
of adjuvant cancer therapies in the future [26, 35].
Surgery-related stress has also been associated 
with tumor relapse by directly enhancing tumor growth 
and modulating the immune microenvironment [10]. In 
our surgical setting, removal of the eyes may produce 
long-term stress that can modulate the activity of the 
macrophages and other immune cells and contribute to 
tumor growth. Interestingly, soluble factors known to be 
associated with surgical stress such as prostaglandins have 
also been shown to promote macrophage polarization to 
the M2 phenotype [36, 37]. Prostaglandins also produce 
immunosuppressive effects by reducing Th1 cytokines 
[38]. While ongoing efforts are focused on enhancing 
immune responses after surgery, for example by treatment 
with IL-12 [39, 40], or boosting NK cell functions 
[41, 42], understanding how immune subsets such as 
macrophages contribute to relapse could lead to the 
development of new therapies. Macrophage depletion, 
as a monotherapy, has already been demonstrated to be 
beneficial in both pre-clinical models [43] and in patients 
[44]. Our study highlights the feasibility of combining 
macrophage depletion with tumor resection to achieve 
better clinical outcomes.
MATERIALS AND METHODS
Mice
Animal care and experimental procedures were 
approved by the Singapore IACUC under protocol 
120742. RETAAD mice were generated as described [45]. 
Male and female mice at 1, 3 and 10–15 weeks of age 
were subjected to visual enucleation and four to six weeks 
later were euthanized and necropsied. Male and female 
mice 30–35 weeks of age were used as aged controls. 
Metastases were identified visually during necropsy, 
removed and photographed with a ruler in the visual field. 
Tumor areas were measured using ImageJ. Eye tumors and 
selected metastases were fixed for immunohistochemistry.
Surgical procedures (visual enucleation)
Mice were injected with Buprenorphine (0.2–1 
mg/kg) and Enrofloxacin (20 mg/kg) prior to surgery 
and anaesthetized with isoflurane during the surgery. 
Both eyes were removed by gently cutting the 
connective tissues around the sclera and severing the 
optic nerve. The orbits were filled with sterile Gelfoam 
(Pharmacia and Upjohn) and the eye lids sutured 
together to close the wound. Following surgery, mice 
were treated with Buprenorphine and Enrofloxacin for 
three days. Mice operated on at 1 week of age were 
returned to the breeding cage after surgery before 
weaning at 3 weeks of age.
Drug administration
Ki20227 (synthesized by GVKBio) was incorporated 
into the Harlan 2918 diet (Harlan) to give an estimated 
effective treatment dose of 30–40 mg/kg/day (drug/mouse 
weight). Mice were fed ad libidum for the duration of the 
experiment. Prior to weaning, pups were given Ki20227 
dissolved in 0.05% methylcellulose by daily oral gavage 
at the same treatment dose as above. Upon weaning, mice 
were transferred to the Ki20227 diet.
Immunohistochemistry
Formalin-fixed paraffin-embedded tumor sections 
(5 μm) were immunolabeled for S100B to identify 
melanoma cells, and for Ki67 to identify proliferating 
cells. Sections were dewaxed in xylene and heat-treated 
in Target Retrieval Solution (DAKO). Non-specific 
antibody binding was blocked by incubating sections 
with 3% (v/v) hydrogen peroxide, biotin and avidin block 
(DAKO) and 10% (v/v) normal goat serum (DAKO). 
Rabbit anti-S100B (DAKO; 1:4,000) and rat anti-Ki67 
(DAKO; 1:40) antibodies were then applied and incubated 
overnight at 4°C. S100B labeling was revealed with 
anti-rabbit HRP (DAKO) and AEC peroxidase substrate 
(Vector Laboratories), while Ki67 labeling was revealed 
with biotinylated donkey anti-rat (Jackson Lab; 1:300) 
followed by alkaline phosphatase-conjugated streptavidin 
(Rockland Inc.; 1:2000) and Alkaline Phosphate Substrate 
Kit III (Vector Laboratories). To visualize immune cells 
within the tumor bed we use anti-S100B (DAKO), CD45-
APC (Biolegend; 1:200) and F4/80-biotin (AbDserotec; 
1:50) antibodies overnight at 4°C. Anti-rabbit-FITC 
(DAKO; 1:500) and streptavidin-PE (Invitrogen; 1:500) 
antibodies were used to reveal S100B and F4/80 labeling 
respectively.
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Cell selection
TIC and immune cell populations were harvested 
from the same mice for each experiment. Tumor cell 
sub-populations were sorted by flow cytometry using 
CD34-biotin (eBioscience), CD45-FITC, PDGFRα-APC 
and CD31-PECy7 (Biolegend) antibodies followed by 
streptavidin-PE. TAMs were isolated using CD45-FITC, 
CD11b-PECy7 (Biolegend), and F4/80-biotin, followed by 
streptavidin-PE.
Cell culture
Tumors were dissociated with collagenase A 
(1 mg/ml) and DNase I (0.1 mg/ml; Roche) and cultured 
in stem cell medium [DMEM/F12 (1:1), 1% penicillin/
streptomycin, B27 supplement (Invitrogen), 10ng/ml 
bFGF and 20ng/ml EGF (Peprotec)] at 4000 cells/cm2 
in ultra-low attachment culture wells (Corning). Culture 
plates were left undisturbed during the culture period 
to avoid stimulating sphere formation by aggregation. 
Spheres greater than 30 μm in diameter were counted 5–7 
days after cell seeding. TAMs were added at a ratio of 1:50 
to tumor cells on the day of seeding and remained for the 
duration of the culture.
Gene expression analysis
Cells were homogenized in TRIZOL (Qiagen). 
RNA was extracted using the Qiagen RNeasy Micro 
kit. cDNA was reverse transcribed (Roche Applied 
Biosystem reagents) and subjected to quantitative PCR 
with SYBR green (Bio-Rad) and specific primers. 
TGFβ (5′-GGCTACCATGCCAACTTCTG-3′ and 5′-G 
CTTGCGACCCACGTAGTAG-3′), Arginase1 (5′-CAA 
GACAGGGCTCCTTTCAG-3′ and 5′-GTAGTCAGTC 
CCTGGCTTATGG-3′), Sms (5′-CAACGTGCTGGT 
TCTGGATG-3′ and 5′-TTGATGAGGTCCAGGTGC 
AG-3′) and APAO (5′- ACTGCCAGTTCATCCAGGTG-3′ 
and 5′-GAGTCTCCATAAACTCCGACTCC-3′). Gene 
expression was normalized to GAPDH (5′-TGCGAC 
TTCAACAGCAACTC-3′ and 5′-ATGTAGGCCATGA 
GGTCCAC-3′).
Statistical analysis
Graphs were generated and statistical analysis was 
carried out using Graphpad Prism 6 software. The tests 
applied are indicated in the figure legends: two-tailed t 
tests were used for comparisons between two groups; one-
way ANOVA was used to compare multiple groups with 
one experimental parameter; and two-way ANOVA was 
used to compare multiple groups with two experimental 
parameters. When multiples tumor nodules were presented 
for each mouse, the statistical analyses were performed 
with the mean value from each mouse.
Additional experimental procedures can be found in 
the Supplemental section.
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